Steve is a respected and well-known expert on recombinant antibodies and immunotherapy and has invented core platform technologies. During the course of his scientific career, Steve has led multiple therapeutic candidates into clinical development for the treatment of cancer and HIV/AIDS.

Previously Steve was founding President of Fuji ImmunoPharmaceuticals which later became Lexigen Pharmaceuticals. After its acquisition by Merck KGaA, he served as President of EMD Lexigen, now known as EMD Serono, and as the Global Head of Oncology Research. Steve earned his BS in microbiology from UMass-Amherst, and his MS and PhD in microbiology from the University of Medicine and Dentistry of New Jersey. He completed his post-doctoral training at the MIT Center for Cancer Research.